Security Snapshot

Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) Institutional Ownership

CUSIP: 89422G107

13F Institutional Holders and Ownership History from Q4 2020 to Q2 2026

Latest Period

Q2 2026

Institutions Reporting

315

Shares (Excl. Options)

105,109,065

Price

$56.81

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+2,907,935
Value change
+$224,247,386
Number of holders
315
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
94,164,012
SEC-reported price per share
$55.56
Insider filing price
$55.56
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • TVTX - Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 89422G107.
  • 315 institutions reported positions in Q2 2026.
  • 10 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 259 to 315 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $3,010,549,700 to $5,968,997,240.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 315 institutions filings for Q2 2026.

Open SEC evidence

Security key

89422G107

Latest holder period

Q2 2026

13F holders

315

13D/G owners

10

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
10
Security
TVTX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JANUS HENDERSON GROUP PLC 12% -6.9% $253,331,874 -$17,690,876 10,599,660 -6.5% JANUS HENDERSON GROUP PLC 30 Sep 2025
FMR LLC 7.7% -33% $410,549,878 -$196,858,711 7,142,482 -32% FMR LLC 30 Jun 2026
BlackRock, Inc. 7.5% -21% $122,617,344 -$24,357,949 6,689,435 -17% BlackRock, Inc. 31 Mar 2025
BANK OF AMERICA CORP /DE/ 5.8% $312,642,629 5,439,155 BANK OF AMERICA CORP /DE/ 30 Jun 2026
VANGUARD CAPITAL MANAGEMENT LLC 5.1% $139,619,887 4,699,424 Vanguard Capital Management 31 Mar 2026
PERCEPTIVE ADVISORS LLC 4.8% -12% $124,537,820 -$17,973,533 4,278,180 -13% Perceptive Advisors LLC 31 Dec 2025
STATE STREET CORP 4.6% -14% $244,647,756 -$28,765,406 4,256,224 -11% STATE STREET CORPORATION 30 Jun 2026
Rock Springs Capital Management LP 3.3% -40% $53,545,523 -$37,621,463 2,921,196 -41% Rock Springs Capital Management LP 31 Mar 2025
Woodline Partners LP 2.4% $38,750,646 2,114,056 Woodline Partners LP 31 Dec 2024
ARMISTICE CAPITAL, LLC 1.7% -72% $90,389,542 -$191,113,987 1,572,539 -68% Armistice Capital, LLC 30 Jun 2026

As of 30 Jun 2026, 315 institutional investors reported holding 105,109,065 shares of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX). This represents 112% of the company’s total 94,164,012 outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
80%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Jupiter Topco LLC 12% 11,324,191 0% 0.26% $643,299,225
BlackRock, Inc. 8.5% 8,020,663 +2.9% 0.01% $455,653,851
FMR LLC 7.5% 7,096,614 -35% 0.02% $403,158,609
BANK OF AMERICA CORP /DE/ 4.9% 4,568,341 +240% 0.02% $259,527,476
STATE STREET CORP 4.5% 4,256,224 -14% 0.01% $241,796,085
VANGUARD CAPITAL MANAGEMENT LLC 4.4% 4,108,694 +1.6% 0% $233,414,906
PERCEPTIVE ADVISORS LLC 4% 3,752,574 -9.4% 3.3% $213,183,729
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 3% 2,812,514 -14% 0.24% $159,779,000
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.7% 2,569,356 +163% 0.2% $145,965,114
GEODE CAPITAL MANAGEMENT, LLC 2.5% 2,371,887 +0.1% 0.01% $134,773,950
Rock Springs Capital Management LP 2.3% 2,179,069 +47% 6% $123,792,910
Kynam Capital Management, LP 2.1% 2,000,000 +27% 6.3% $113,620,000
Stephens Investment Management Group LLC 2% 1,875,304 +4.3% 1.1% $106,536,020
RENAISSANCE TECHNOLOGIES LLC 1.9% 1,833,079 -6.8% 0.14% $104,137,218
EMERALD ADVISERS, LLC 1.7% 1,600,886 +2.8% 2.1% $90,946,334
ARMISTICE CAPITAL, LLC 1.7% 1,572,539 -68% 2.5% $89,335,941
TWO SIGMA INVESTMENTS, LP 1.7% 1,565,656 +3.8% 0.07% $88,944,917
VANGUARD PORTFOLIO MANAGEMENT LLC 1.6% 1,541,617 -9.8% 0% $87,579,262
GOLDMAN SACHS GROUP INC 1.6% 1,535,321 -11% 0.01% $87,221,587
WELLINGTON MANAGEMENT GROUP LLP 1.6% 1,533,080 +50% 0.02% $87,094,276
Qube Research & Technologies Ltd 1.5% 1,443,230 +116% 0.09% $81,989,896
D. E. Shaw & Co., Inc. 1.5% 1,440,469 +72% 0.05% $81,833,044
Driehaus Capital Management LLC 1.5% 1,439,134 +12% 0.47% $81,757,203
MARSHALL WACE, LLP 1.4% 1,333,207 +647% 0.06% $75,739,490
PRICE T ROWE ASSOCIATES INC /MD/ 1.4% 1,318,616 +226% 0.01% $74,911,000

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
23
Latest
Q2 2026
Rows shown
1-23 of 23
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 105,109,065 $5,968,997,240 +$224,247,386 $56.81 315
2026 Q1 101,356,345 $3,010,549,700 -$45,748,182 $29.71 259
2025 Q4 102,162,218 $3,903,903,645 +$7,451,854 $38.21 276
2025 Q3 100,727,863 $2,407,390,168 +$19,761,610 $23.90 235
2025 Q2 100,531,635 $1,487,836,300 +$12,972,115 $14.80 207
2025 Q1 98,007,579 $1,771,747,554 +$87,075,624 $17.92 214
2024 Q4 95,064,656 $1,655,970,325 +$204,069,962 $17.42 194
2024 Q3 82,734,245 $1,157,476,987 -$64,293,173 $13.99 175
2024 Q2 87,955,117 $723,000,948 +$2,540,410 $8.22 168
2024 Q1 87,706,388 $676,170,447 +$11,374,907 $7.71 172
2023 Q4 85,573,515 $769,316,791 +$27,493,568 $8.99 162
2023 Q3 82,430,217 $736,935,857 -$48,196,261 $8.94 166
2023 Q2 82,714,633 $1,270,488,775 -$85,984,898 $15.36 165
2023 Q1 84,151,882 $1,892,538,812 +$263,849,900 $22.49 171
2022 Q4 72,978,794 $1,535,405,782 +$36,464,951 $21.03 153
2022 Q3 69,779,173 $1,719,469,986 -$2,015,044 $24.64 168
2022 Q2 69,489,567 $1,683,983,339 +$17,370,839 $24.23 166
2022 Q1 69,479,485 $1,789,961,946 +$97,223,694 $25.77 166
2021 Q4 65,477,167 $2,032,139,426 +$61,452,684 $31.04 165
2021 Q3 60,858,590 $1,476,104,164 +$4,235,576 $24.25 145
2021 Q2 60,583,594 $883,983,031 -$73,514,650 $14.59 131
2021 Q1 62,621,768 $1,563,390,183 +$254,685,025 $24.97 147
2020 Q4 52,293,956 $1,423,328,983 +$1,416,953,984 $27.26 135
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .